Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Formoterol
Drug: Salmeterol
Drug: Placebo

First Posted Date: 2010-01-13

Last Posted Date: 2012-10-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 109

Registration Number: NCT01048333

Locations: 🇸🇪
Research Site, Lund, Sweden

Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins

Completed

Conditions: Dyslipidemia
Coronary Heart Disease

First Posted Date: 2010-01-12

Last Posted Date: 2012-03-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 602

Registration Number: NCT01047176

Locations: 🇷🇺
Research Site, Moscow, Russian Federation

A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD7687
Drug: Placebo

First Posted Date: 2010-01-12

Last Posted Date: 2012-02-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 64

Registration Number: NCT01046357

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

Phase 1

Completed

Conditions: Depression

Interventions: Drug: AZD6765
Drug: Placebo
Drug: Ketamine

First Posted Date: 2010-01-12

Last Posted Date: 2014-10-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 128

Registration Number: NCT01046630

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: Aclidinium bromide

First Posted Date: 2010-01-08

Last Posted Date: 2017-01-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 544

Registration Number: NCT01045161

Locations: 🇺🇸
Forest Investigative Site 1386, Atlanta, Georgia, United States
🇺🇸
Forest Investigative Site 1433, Columbus, Ohio, United States
🇺🇸
Forest Investigative Site 1517, Easley, South Carolina, United States

and more 109 locations

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Aclidinium Bromide 400 µg
Drug: Aclidinium Bromide 200 µg

First Posted Date: 2010-01-07

Last Posted Date: 2017-04-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 605

Registration Number: NCT01044459

Locations: 🇺🇸
Forest Investigative Site 1328, Dallas, Texas, United States
🇨🇦
Forest Investigative Site 1168, Toronto, Ontario, Canada
🇺🇸
Forest Investigative Site 1432, Miami, Florida, United States

and more 110 locations

A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

Phase 1

Completed

Conditions: Cognition

Interventions: Drug: AZD1446
Drug: Placebo
Drug: donepezil

First Posted Date: 2010-01-07

Last Posted Date: 2010-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT01044342

Locations: 🇫🇷
Research Site, Rouffach, France

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Phase 3

Completed

Conditions: Cardiovascular Disease
Type 2 Diabetes Mellitus
Inadequate Glycaemic Control

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2010-01-06

Last Posted Date: 2014-02-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 964

Registration Number: NCT01042977

Locations: 🇵🇱
Research Site, Zielona Gora, Poland

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Phase 2

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: AZD3355
Drug: placebo

First Posted Date: 2010-01-06

Last Posted Date: 2011-06-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT01043185

Locations: 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States

Connection Between General Practitioner's (GP's) Estimation of Cardiovascular Risk and Theoretical Calculation in France

Completed

Conditions: Cardiovascular Risk

First Posted Date: 2009-12-25

Last Posted Date: 2010-09-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 13502

Registration Number: NCT01039402

Locations: 🇫🇷
Research Site, Woerth, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy